# A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

> **NCT06994143** · PHASE1 · RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 37 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA

## Interventions

- **DRUG:** CLN-978

## Key facts

- **NCT ID:** NCT06994143
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994143, "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06994143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*